Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

28.78USD
17 Aug 2018
Change (% chg)

$1.56 (+5.73%)
Prev Close
$27.22
Open
$27.31
Day's High
$28.86
Day's Low
$27.04
Volume
433,278
Avg. Vol
518,862
52-wk High
$136.45
52-wk Low
$25.62

Latest Key Developments (Source: Significant Developments)

Tesaro Enters Asset Purchase Agreement With Tersera® Therapeutics LLC For Varubi® In The U.S. And Canada
Thursday, 28 Jun 2018 04:05pm EDT 

June 28 (Reuters) - TESARO Inc ::TESARO ENTERS ASSET PURCHASE AGREEMENT WITH TERSERA® THERAPEUTICS LLC FOR VARUBI® IN THE U.S. AND CANADA.TESARO TO RECEIVE $40 MILLION, PLUS POTENTIAL FOR ADDITIONAL MILESTONE PAYMENTS AND ROYALTIES.TESARO - ENTERED AGREEMENT WITH TERSERA THERAPEUTICS UNDER WHICH IT WILL DIVEST NORTH AMERICAN RIGHTS TO ORAL AND INTRAVENOUS FORMULATIONS OF VARUBI.TESARO RETAINS EX-NORTH AMERICA RIGHTS AND CONTINUES TO MARKET VARUBY IN EUROPE.CO TO RECEIVE MILESTONE PAYMENT AND ROYALTIES ON ANNUAL NET SALES ON ANY NEW INTRAVENOUS FORMULATION OF ROLAPITANT DEVELOPED BY TERSERA.OF $40 MILLION INITIAL PURCHASE PRICE, $35 MILLION WILL BE PAID AT CLOSING AND $5 MILLION WILL BE PAID EIGHTEEN MONTHS AFTER CLOSING.  Full Article

Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel
Wednesday, 11 Apr 2018 08:30am EDT 

April 11 (Reuters) - TESARO Inc ::TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULA® IN ISRAEL.FURTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.MEDISON WILL HAVE EXCLUSIVE RIGHT TO COMMERCIALIZE ZEJULA IN ALL INDICATIONS, EXCLUDING PROSTATE CANCER, IN ISRAEL.MEDISON TO ALSO BE RESPONSIBLE FOR ANY POTENTIAL PATIENT ACCESS PROGRAMS PRIOR TO REGULATORY APPROVAL.  Full Article

Tesaro Inc Q4 Loss Per Share $3.35
Tuesday, 27 Feb 2018 04:05pm EST 

Feb 27 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS.Q4 LOSS PER SHARE $3.35.Q4 REVENUE $48 MILLION VERSUS $4.9 MILLION.SEES 2018 TOTAL REVENUE, NET, WORLDWIDE (FY) IN RANGE $310 MLNTO $345 MILLION.TESARO - ANTICIPATES CASH AND CASH EQUIVALENTS BALANCE TO DECLINE BY $150 MILLION DURING Q1.QUARTERLY DECLINES IN CASH AND CASH EQUIVALENTS ARE EXPECTED TO MODERATE OVER COURSE OF 2018, AND IN Q4 OF 2018.PLANS TO DRAW $200 MILLION IN 2018 FROM ITS AVAILABLE TERM LOAN FACILITY.ANTICIPATES YEAR-END 2018 CASH AND CASH EQUIVALENTS TO BE APPROXIMATELY $400 MILLION.  Full Article

Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer
Monday, 26 Feb 2018 03:00pm EST 

Feb 26 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER.TESARO INC - ‍PLANNED TRIAL WILL BE CONDUCTED BY GENENTECH AND IS EXPECTED TO BEGIN MID-2018​.TESARO INC - ‍COLLABORATION INCLUDES TESTING EXPERIMENTAL COMBINATION IN MORPHEUS, ROCHE'S CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM​.  Full Article

Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion
Friday, 12 Jan 2018 05:30pm EST 

Jan 12 (Reuters) - Tesaro Inc ::TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION.TESARO INC - CHANGES TO LABELING INCLUDE MODIFICATIONS TO CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, AND ADVERSE REACTIONS SECTIONS.TESARO - ANAPHYLAXIS, ANAPHYLACTIC SHOCK HAVE BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING, SOME REQUIRING HOSPITALIZATION.TESARO - OTHER "SERIOUS" HYPERSENSITIVITY REACTIONS HAVE ALSO BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING.TESARO - MOST REACTIONS HAVE OCCURRED DURING OR SOON AFTER INFUSION OF VARUBI INJECTABLE EMULSION AND WITHIN FIRST FEW MINUTES OF ADMINISTRATION.  Full Article

Tesaro secures $500 million non-dilutive term loan financing
Tuesday, 21 Nov 2017 08:00am EST 

Nov 21 (Reuters) - Tesaro Inc :Tesaro secures $500 million non-dilutive term loan financing.Loans will mature in December 2024​.Loan facility provides Tesaro with up to $500 million of borrowing capacity available in two tranches​.Plan to use proceeds to strengthen PARP inhibitor franchise in ovarian cancer, expand development of Zejula in other tumor types​.  Full Article

Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Tesaro Inc :Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer.Tesaro Inc - ‍approval supported by "robust" data from a randomized phase 3 trial​.Tesaro Inc - ‍Tesaro plans to launch Zejula in Germany and UK this December, with launches in additional European countries to follow beginning in 2018​.  Full Article

Tesaro reports Q3 loss per share $0.47
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Tesaro Inc ::Tesaro announces third-quarter 2017 operating results.Q3 loss per share $0.47.Q3 revenue $142.8 million versus I/B/E/S view $132.8 million.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Tesaro Inc - ‍positive CHMP opinion issued for zejula in e.u. & commercial launch anticipated to begin by year-end​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 10:19am EDT 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

EU Medicines Agency publishes recommendations for Sept 2017
Friday, 15 Sep 2017 07:55am EDT 

Sept 15 (Reuters) - EU MEDICINES AGENCY::EU MEDICINES AGENCY RECOMMENDS APPROVAL OF TESARO INC'S <<>> NIRAPARIB DRUG FOR TREATMENT OF RECURRENT OVARIAN CANCER.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF JANSSEN-CILAG INTERNATIONAL N.V.'S GUSELKUMAB DRUG FOR TREATMENT OF PLAQUE PSORIASIS.  Full Article

UPDATE 2-European shares enjoy timid rebound though trade war fears linger

* France's CAC 40 underperforms as luxury stocks fall (Updates prices, adds details)